The U.S. Food and Drug Administration (FDA) will meet Cognition during a Type C meeting scheduled for the second half of January 2026. During the meeting, the next clinical studies for zervimesine in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback